Mufson E, He B, Ginsberg S, Carper B, Bieler G, Crawford F
J Neurotrauma. 2018; 35(11):1260-1271.
PMID: 29338612
PMC: 5962931.
DOI: 10.1089/neu.2017.5368.
Smucny J, Tregellas J
J Psychopharmacol. 2017; 31(7):801-811.
PMID: 28441884
PMC: 5963521.
DOI: 10.1177/0269881117705071.
Kuwabara H, Gao Y, Stabin M, Coughlin J, Nimmagadda S, Dannals R
Mol Imaging Biol. 2016; 19(2):280-288.
PMID: 27562686
DOI: 10.1007/s11307-016-0999-9.
Lewis A, Picciotto M
Psychopharmacology (Berl). 2013; 229(3):477-85.
PMID: 23624811
PMC: 3766461.
DOI: 10.1007/s00213-013-3126-5.
Chen J, Brunzell D, Jackson K, van der Vaart A, Ma J, Payne T
PLoS One. 2011; 6(12):e28790.
PMID: 22205969
PMC: 3243669.
DOI: 10.1371/journal.pone.0028790.
Lower ß2*-nicotinic acetylcholine receptor availability in smokers with schizophrenia.
DSouza D, Esterlis I, Carbuto M, Krasenics M, Seibyl J, Bois F
Am J Psychiatry. 2011; 169(3):326-34.
PMID: 22193533
PMC: 3881431.
DOI: 10.1176/appi.ajp.2011.11020189.
Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.
Jones C, Byun N, Bubser M
Neuropsychopharmacology. 2011; 37(1):16-42.
PMID: 21956443
PMC: 3238081.
DOI: 10.1038/npp.2011.199.
A CHRNA5 allele related to nicotine addiction and schizophrenia.
Hong L, Yang X, Wonodi I, Hodgkinson C, Goldman D, Stine O
Genes Brain Behav. 2011; 10(5):530-5.
PMID: 21418140
PMC: 3126887.
DOI: 10.1111/j.1601-183X.2011.00689.x.
Cholinergic contributions to the cognitive symptoms of schizophrenia and the viability of cholinergic treatments.
Sarter M, Lustig C, Taylor S
Neuropharmacology. 2010; 62(3):1544-53.
PMID: 21156184
PMC: 3920544.
DOI: 10.1016/j.neuropharm.2010.12.001.
Single photon emission computed tomography experience with (S)-5-[(123)I]iodo-3-(2-azetidinylmethoxy)pyridine in the living human brain of smokers and nonsmokers.
Brasic J, Zhou Y, Musachio J, Hilton J, Fan H, Crabb A
Synapse. 2009; 63(4):339-58.
PMID: 19140167
PMC: 2766259.
DOI: 10.1002/syn.20611.
Smoking, Genetics and Schizophrenia: Evidence for Self Medication.
Leonard S, Mexal S, Freedman R
J Dual Diagn. 2009; 3(3-4):43-59.
PMID: 19122786
PMC: 2613326.
DOI: 10.1300/J374v03n03_05.
Neuronal Ca2+ sensor VILIP-1 leads to the upregulation of functional alpha4beta2 nicotinic acetylcholine receptors in hippocampal neurons.
Zhao C, Noack C, Brackmann M, Gloveli T, Maelicke A, Heinemann U
Mol Cell Neurosci. 2008; 40(2):280-92.
PMID: 19063970
PMC: 2683982.
DOI: 10.1016/j.mcn.2008.11.001.
Genetic association analysis of tagging SNPs in alpha4 and beta2 subunits of neuronal nicotinic acetylcholine receptor genes (CHRNA4 and CHRNB2) with schizophrenia in the Japanese population.
Kishi T, Ikeda M, Kitajima T, Yamanouchi Y, Kinoshita Y, Kawashima K
J Neural Transm (Vienna). 2008; 115(10):1457-61.
PMID: 18762859
DOI: 10.1007/s00702-008-0114-8.
Subtypes of nicotinic acetylcholine receptors in nicotine reward, dependence, and withdrawal: evidence from genetically modified mice.
Fowler C, Arends M, Kenny P
Behav Pharmacol. 2008; 19(5-6):461-84.
PMID: 18690103
PMC: 2669417.
DOI: 10.1097/FBP.0b013e32830c360e.
A neurocognitive animal model dissociating between acute illness and remission periods of schizophrenia.
Sarter M, Martinez V, Kozak R
Psychopharmacology (Berl). 2008; 202(1-3):237-58.
PMID: 18618100
PMC: 2719245.
DOI: 10.1007/s00213-008-1216-6.
Stimulation of the alpha4beta2 nicotinic receptor by 5-I A-85380 improves auditory gating in DBA/2 mice.
Wildeboer K, Stevens K
Brain Res. 2008; 1224:29-36.
PMID: 18582447
PMC: 2596929.
DOI: 10.1016/j.brainres.2008.06.007.
Effects of nicotine on sensorimotor gating impairment induced by long-term treatment with neurotoxic NMDA antagonism.
Rasmussen B, Perry D, ONeil J, Manaye K, Tizabi Y
Neurotox Res. 2008; 13(3-4):151-61.
PMID: 18522895
DOI: 10.1007/BF03033499.
A risk allele for nicotine dependence in CHRNA5 is a protective allele for cocaine dependence.
Grucza R, Wang J, Stitzel J, Hinrichs A, Saccone S, Saccone N
Biol Psychiatry. 2008; 64(11):922-9.
PMID: 18519132
PMC: 2582594.
DOI: 10.1016/j.biopsych.2008.04.018.
Nicotine and nicotinic system in hypoglutamatergic models of schizophrenia.
Tizabi Y
Neurotox Res. 2008; 12(4):233-46.
PMID: 18201951
DOI: 10.1007/BF03033907.
Association of alpha4beta2 nicotinic receptor and heavy smoking in schizophrenia.
Voineskos S, De Luca V, Mensah A, Vincent J, Potapova N, Kennedy J
J Psychiatry Neurosci. 2007; 32(6):412-6.
PMID: 18043764
PMC: 2077346.